|

Androgen deprivation therapy (ADT) Clinical Trials

16 actively recruiting trials across 5 locations

▲ +1 trial since August 2026

Also known as: ADT, Degarelix, Leuprolide, Relugolix

Pipeline

Phase 1: 1Phase 2: 8Phase 3: 3Phase 2/3: 2

Top Sponsors

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School2
  • NYU Langone Health2
  • Affidea Nu-med Center of Oncological DIagnostics and Therapy2
  • University of Texas Southwestern Medical Center1
  • University of Nebraska1

Indications

  • Cancer16
  • Prostate Cancer11
  • Dose Escalation: Solid Tumors2
  • Stereotactic Body Radiation Therapy (SBRT)2
  • Biochemical Recurrence2

Other8 trials

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
Phase 3
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
Phase 2
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
N/A
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
Phase 2/3
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
Phase 2/3
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
Phase 3
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Phase 2
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Phase 2

New York, New York3 trials

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

Memorial Sloan Kettering Cancer Center

Phase 2
Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

NYU Langone Health

Phase 2
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)

NYU Langone Health

N/A

Dallas, Texas2 trials

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Mary Crowley Cancer Research

Phase 1
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

UT Southwestern Medical Center-Dallas

Phase 2

Phoenix, Arizona1 trial

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Research Site

Phase 3

Chicago, Illinois1 trial

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

UChicago Medicine Comprehensive Cancer Center

Phase 2

Omaha, Nebraska1 trial

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

University of Nebraska Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.